Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million
Press Release – New York, NY – June 10, 2019 – Sichenzia Ross Ference LLP announced today that it has represented Medicine Man Technologies, Inc. (OTC: MDCL) (“Medicine Man or the “Company”) in a securities purchase agreement with Dye Capital & Co. for the sale of up to $14 million of shares and common stock purchase warrants of the Company. The shares were sold at a price of $2.00 per share.
The warrants are exercisable for three years at an exercise price of $3.50. The securities purchase agreement provides for the sale of the shares in tranches with an initial closing held on June 6, 2019. At the initial closing, the Company issued and sold 1,500,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock, for gross proceeds of $3,000,000.
Denver, Colorado based Medicine Man, is a fully integrated operator in the cannabis industry, offering consulting, retail pharma-grade products, and turnkey solutions for cannabis cultivators for over a decade. Medicine Man is leveraging its expertise and intellectual property to vertically integrate retail, cultivation, formulation, and distribution operations. The Company’s client portfolio includes active and past clients in 18 states and seven countries. The Company has recently announced the entry into binding term sheets to acquire, MedPharm Holdings, Medicine Man Dence, Los Sueños Farms and Mesa Organics on the heels of the signing of six cannabis related bills, including HB-19-1090 passed into law by the Colorado legislature on May 29, 2019.
The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia and Marcelle Balcombe and associate Jacob Tabman.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021